# PD-L1 in triple-negative breast cancer

3 EU-approved indications in triple-negative breast cancer need a PD-L1 result: pembrolizumab (1st line, advanced), sacituzumab govitecan (1st line, advanced) and atezolizumab (1st line, advanced).

## Approved indications

### PD-L1

| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| [Atezolizumab](https://oncolabels.com/drugs/atezolizumab) (Tecentriq) | PD-L1 IC ≥ 1% | + nab-paclitaxel | 1st line, advanced | No prior chemotherapy for metastatic disease |
| [Pembrolizumab](https://oncolabels.com/drugs/pembrolizumab) (Keytruda) | PD-L1 CPS ≥ 10 | + chemotherapy | 1st line, advanced | No prior chemotherapy for metastatic disease |
| [Sacituzumab govitecan](https://oncolabels.com/drugs/sacituzumab-govitecan) (Trodelvy) | PD-L1 CPS ≥ 10 | + pembrolizumab | 1st line, advanced | No prior systemic therapy for metastatic disease |

## Label wording

- **Pembrolizumab** (Keytruda), Triple-negative breast cancer, 1st line, advanced: “KEYTRUDA, in combination with chemotherapy, is indicated for the treatment of locally recurrent unresectable or metastatic triple-negative breast cancer in adults whose tumours express PD-L1 with a CPS ≥ 10 and who have not received prior chemotherapy for metastatic disease (see section 5.1).” [SmPC](https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf)
- **Sacituzumab govitecan** (Trodelvy), Triple-negative breast cancer, 1st line, advanced: “in combination with pembrolizumab, for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic disease and whose tumours express PD-L1 with a combined positive score (CPS) ≥ 10 (see sections 4.2 and 5.1).” [SmPC](https://www.ema.europa.eu/en/documents/product-information/trodelvy-epar-product-information_en.pdf)
- **Atezolizumab** (Tecentriq), Triple-negative breast cancer, 1st line, advanced: “Tecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumours have PD-L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf)

Source: section 4.1 of each summary of product characteristics (SmPC), EMA data as of 5 Nov 2026. AI models structured these entries and no person has checked them yet. oncolabels is a non-commercial reference for education and research and gives no medical advice; the current SmPC takes precedence.

Data under CC BY 4.0: credit oncolabels and the European Medicines Agency. Page: https://oncolabels.com/tumours/triple-negative-breast-cancer/pd-l1